What is Walvax Biotechnology Co., Ltd.'s (300142.SZ) StockRank?

MoatMap's StockRank for Walvax Biotechnology Co., Ltd. (300142.SZ) is 67/100, with a Buy signal. This is a composite score combining Quality (54), Value (26), and Momentum (75) factor ranks across MoatMap's 19,000+ stock universe.

Does Walvax Biotechnology Co., Ltd. have an economic moat?

Walvax Biotechnology Co., Ltd. (300142.SZ) has a Quality factor score of 54/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Walvax Biotechnology Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Walvax Biotechnology Co., Ltd. (300142.SZ) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Walvax Biotechnology Co., Ltd. in?

Walvax Biotechnology Co., Ltd. (300142.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300142.SZ

BUYREMOVE

Walvax Biotechnology Co., Ltd. · Healthcare · China · $3.0B · Avg Vol: $152M/d

StockRank

P/E (TTM)

64.3x

ROE

2.7%

D/E

0.2x

Dividend %

1.3%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Walvax Biotechnology is a vaccine developer. It does not operate as a CDMO and therefore does not benefit from the CDMO pricing power cycle, while carrying high binary R&D risks.

COMPANY DESCRIPTION

Walvax Biotechnology Co., Ltd. is a leading Chinese biopharmaceutical company specializing in the research, development, and production of human vaccines. Its product portfolio includes blockbuster products like the 13-valent pneumococcal conjugate vaccine (PCV13) and HPV vaccines, positioning it as a key player in China's domestic immunization market. The company's competitive moat is sustained by its advanced vaccine technology platforms, including mRNA and recombinant protein technologies, and a robust commercialization network.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	752M	608M	417M	357M	-22.0%
EPS	0.07	0.04	0.01	0.02	-37.5%
Shares	1.6B	1.6B	1.6B	1.6B	-0.5%
Debt	68M	119M	73M	57M	-5.6%
Equity	1.3B	1.4B	1.4B	1.3B	-1.7%
Op CF	178M	168M	153M	73M	-25.8%
Inv CF	-138M	-119M	-187M	-47M	—
Fin CF	14M	35M	-55M	-382M	—

PRICE (1M)-8.4%

SMA 50SMA 200

$1.79

RSI (14)

34.9

52W High

$2.40

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

1.6%47.5

ROE

2.7%49.9

GP/Assets

14.6%34.3

Op. Margin

33.7%94.4

FCF/Assets

-4.6%36.6

Piotroski

—83.5

Int. Cover

50.0x91.4

D/E Ratio

0.17x55.4

Current Ratio

2.16x40.2

Value

P/E (TTM)

64.3x15.2

EV/EBITDA

30.8x11.3

P/FCF

—N/A

P/B

2.5x46.5

P/S

7.7x30.6

Div Yield

1.3%36.6

Momentum

52W High %

75%64.4

RS 6M

-4%74.5

SMA 50/200

1.05x72.0

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—82.4

Q Growth

4082%99.2

FUNDAMENTALS

Market Cap

$3.0B

P/E (Forward)

25.7x

Gross Margin

73.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300142.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300142.SZ	Walvax Biotechnology Co., Ltd.(you)	$3.0B	67	BUY
000623.SZ	Jilin Aodong Pharmaceutical Group Co., Ltd.	$3.0B	69	BUY
603858.SS	Shandong Buchang Pharmaceuticals Co., Ltd.	$2.3B	66	BUY
002399.SZ	Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	$2.2B	67	BUY
002317.SZ	Guangdong Zhongsheng Pharmaceutical Co., Ltd.	$3.0B	60	HOLD
002773.SZ	Chengdu Kanghong Pharmaceutical Group Co., Ltd	$2.9B	75	BUY
301246.SZ	Hubei Hongyuan Pharmaceutical Technology Co., Ltd.	$1.9B	66	BUY
600085.SS	Beijing Tongrentang Co., Ltd	$5.2B	67	BUY
603707.SS	Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.	$1.9B	65	BUY
002262.SZ	Jiangsu Nhwa Pharmaceutical Co., LTD	$3.0B	79	BUY

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.0%

Walvax Biotechnology Co., Ltd. (300142.SZ) — Stock Score Summary

Walvax Biotechnology Co., Ltd. (300142.SZ) has a MoatMap StockRank of 67/100 based on Quality (54/100), Value (26/100), and Momentum (75/100) factor scores. The current signal is BUY. Walvax Biotechnology is a vaccine developer. It does not operate as a CDMO and therefore does not benefit from the CDMO pricing power cycle, while carrying high binary R&D risks.

Key Financial Metrics

Price	$1.79
Market Cap	$3.0B
P/E (TTM)	64.28
P/E (Forward)	25.71
Price/Book	2.50
Return on Equity	2.7%
Return on Invested Capital	1.6%
Debt/Equity	17.44
Gross Margin	73.3%
Operating Margin	33.7%
Revenue Growth	-4.0%
Dividend Yield	1.3%
Free Cash Flow	$-12M

Walvax Biotechnology Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Walvax Biotechnology Co., Ltd.’s (300142.SZ) StockRank?: MoatMap’s StockRank for Walvax Biotechnology Co., Ltd. (300142.SZ) is 67/100, with a Buy signal. It is a composite of Quality (54), Value (26), and Momentum (75) factor ranks across MoatMap’s 19,000+ stock universe.
Does Walvax Biotechnology Co., Ltd. have an economic moat?: Walvax Biotechnology Co., Ltd. (300142.SZ) has a Quality factor score of 54/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Walvax Biotechnology Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Walvax Biotechnology Co., Ltd. (300142.SZ) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Walvax Biotechnology Co., Ltd. in?: Walvax Biotechnology Co., Ltd. (300142.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).